Sector
PharmaceuticalsOpen
₹3.72Prev. Close
₹3.57Turnover(Lac.)
₹0Day's High
₹3.72Day's Low
₹3.452 Week's High
₹052 Week's Low
₹0Book Value
₹10Face Value
₹10Mkt Cap (₹ Cr.)
1.7P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2013 | Mar-2012 | Mar-2011 | Mar-2010 |
---|---|---|---|---|
Equity Capital | 4.99 | 4.99 | 4.99 | 4.99 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -7.53 | -7.48 | -7.44 | -7.38 |
Net Worth | -2.54 | -2.49 | -2.45 | -2.39 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2013 | Mar-2012 |
---|---|---|
Revenue | 0 | 0 |
yoy growth (%) | 0 | |
Raw materials | 0 | 0 |
As % of sales | 0 | 0 |
Employee costs | 0 | 0 |
Y/e 31 Mar( In .Cr) | Mar-2013 | Mar-2012 |
---|---|---|
Profit before tax | -0.04 | -0.03 |
Depreciation | -0.01 | -0.01 |
Tax paid | 0 | 0 |
Working capital | 0 | |
Other operating items |
Y/e 31 Mar | Mar-2013 | Mar-2012 |
---|---|---|
Growth matrix (%) | ||
Revenue growth | 0 | |
Op profit growth | 38.75 | |
EBIT growth | 21.57 | |
Net profit growth | 21.39 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,732.55 | 131.95 | 4,15,696.78 | 1,181.05 | 0.78 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,931 | 75.95 | 1,57,449.41 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,458.35 | 25.31 | 1,17,778.39 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,190.6 | 59.19 | 1,07,979.55 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,507.2 | 53.49 | 1,03,438.77 | 416.38 | 0 | 2,396.57 | 334.18 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
CH Sri Saila Babu
Chairman
A Ramkrishna
Director
M Ranga Rao
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Venkat Pharma Ltd
Summary
Venkat Pharma Ltd manufactures and exports pharmaceutical products in India. The company manufactures Pharmaceutical Finished Doses, Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Nutraceuticals or Dietary Supplements.The companys products include active pharmaceutical ingredients, such as omeprazole powder, omeprazole magnesium, lansoprazole powder, esomeprazole magnesium trihydrate, rabeprazole sodium, pantoprazole sodium sesiquihydrate, olanzapine, citalopram hydrobromide, celecoxib, itraconazole, guaiphenesin verapamil glibenclamide, ciprofloxacin HCL and ofloxacin.The company also offers pharmaceutical formulation intermediates, including omeprazole pellets, lansoprazole pellets, itraxonazole pellets, domperidone pellets, diltiazem pellets, guaiphenesin granules, guaiphenesin granules, dried ferrous sulphate pellets, zinc sulphate pellets, folic acid pellets, pantoprazole pellets, esomeprazole magnesium pellets, rabeprazole pellets, and venlafaxine hydrochloride pellets.In addition, the company provides finished dosages, such as anti bacterial products, anti-hypertensive, NSAIDS and cephalosporins, as well as anti-arthritis, anti-depressants, lipid lowering agent, anti-diabetic, anti-psychotics, anti-pyritic, anti-malarial, anti-TB, and anti-arthritic products. Further, they offer nutraceuticals, over-the-counter products for regulated markets, branded formulations, generic formulations, and dietary supplements.Venkat Pharma
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.